<DOC>
	<DOCNO>NCT02278861</DOCNO>
	<brief_summary>Actinic keratosis ( AKs ) premalignant disorder evolve skin cancer . To prevent development , study conduct oral isotretinoin topical tretinoin verify drug effective best security profile patient . Along treatment , cryotherapy liquid nitrogen sunscreens part treatment . The study duration 10 month . In first four month , AKs count treated cryotherapy ( face arm ) sunscreens FPS 60 use . After , patient return ( AKs count ) , new session cryotherapy perform randomize two group : one group use oral isotretinoin 10mg/day ( ISO : 30 patient ) one use tretinoin 0,05 % cream ( AR : 30 patient ) apply face arm . Skin biopsies do 60 patient begin treatment retinoids ( isotretinoin tretinoin ) . After six month treatment retinoids , study stop , AKs count skin biopsy do . Patients group ISO ( oral isotretinoin ) also make blood test begin , two month six month treatment . Clinical ( AK count ) , histological ( improvement part skin ) immunohistochemical parameter evaluate see drug effective prevention AKs .</brief_summary>
	<brief_title>Oral Isotretinoin Versus Topical Tretinoin Actinic Keratosis</brief_title>
	<detailed_description>This study randomize control trial 60 men woman ( already menopause least one year ) , age 50-75 year . At begin , number actinic keratosis ( AKs ) face forearm count treated cryotherapy liquid nitrogen ( LN ) .The patient randomize two group : one receive oral isotretinoin 10mg/day every day receive tretinoin 0,05 % cream apply face arm every night , six month . Along treatment , patient use sunscreen FPS 60 UVA UVB protection . The inclusion criterion presence least 10 maximum 40 AKs ( visible palpable ) . Skin biopsy perform twice ( treatment retinoids ) patient , leave forearm standardized site . Histological immunohistochemical blinded- evaluator analysis do . The main objective study evaluate clinical , histological immunohistochemical effect retinoids AK prevention face forearm immunocompetent individual . Efficacy evaluation measure improve clinical ( AK count treatment ) , histopathological ( Hematoxilin-eosin Verhoeff stain ) immunohistochemical parameter ( marker carcinogenesis - p53 protein , Bcl-2 Bax ) . The secondary objective evaluate tolerability safety drug impact quality life . The safety analysis related adverse event two drug blood test perform ISO group patient . Indirectly , decrease number AKs expression cutaneous carcinogenesis marker , decrease risk squamous cell carcinoma could infer . This principle use many drug call chemoprophylactic drug , retinoids consider group .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<criteria>1 . Signature Free Clarified Consent Term procedure study ; 2 . Men woman , age 5075 year , good health ; 3 . Women menopause 1 year ; 4 . Phototypes IIV Fitzpatrick classification ; 5 . Glogau photodamage classification scale moderate severe 6 . At least 10 maximum 60 visible and/or palpable actinic keratosis , face forearm , standardized distribution ; 7 . Absence topical treatment face forearm , except sunscreen , : tretinoin last 6 month ; alphahydroxyacids , polyhydroxyacids , betahydroxyacids ascorbic acid last 3 month ; drug procedure may change natural evolution actinic keratosis , imiquimod 5 % cream , diclofenac 3 % hyauronic acid gel , photodynamic therapy , 5FU , last 6 month ; 8 . Absence previous treatment face forearm chemical peel microdermabrasion , last 6 month ; 9 . Absence previous treatment oral retinoids last 6 month ; 10 . Absence anticancer chemotherapy last 3 month ; 11 . Absence hypersensitivity parabens ( present majority drug preserve agent ) ; 12 . Absence infectious inflammatory disease face forearm ; 13 . Absence immunossupression ; 14 . Absence photodermatosis ; 15 . Agreement avoid sun exposure research ; 16 . Agreement perform kind treatment could change natural history actinic keratosis ; 17 . Agreement study condition , ability understand follow strictly give orientation , availability attend periodical evaluation . For isotretinoin group ( ISO ) : 1 . Absence history isotretinoin hypersensitivity ; 2 . Avoid alcohol intake ; 3 . Absence previous actual history rheumatologic disease . For tretinoin group ( AR ) : 1 . Absence history tretinoin hypersensitivity ; For patient : 1 . Men woman d√≥ n't agree term research without ability understand and/or follow strictly condition study , without availability understand attend periodical evaluation decline sign Free Clarified Consent Term ; 2 . Patients le 10 60 actinic keratosis face forearm ; 3 . Fertile , pregnant lactate woman ; 4 . Fitzpatrick phototypes V e VI ; 5 . Topical treatment face forearm , except sunscreen , : tretinoin last 6 month ; alphahydroxyacids , polyhydroxyacids , betahydroxyacids ascorbic acid last 3 month ; drug procedure may change natural evolution actinic keratosis , imiquimod 5 % cream , diclofenac 3 % hyauronic acid gel , photodynamic therapy , 5FU , last 6 month ; 6 . Previous treatment face forearm chemical peel microdermabrasion , last 6 month ; 8 . Previous treatment oral retinoids last 6 month For isotretinoin group ( ISO ) : 1 . Presence significative hepatic laboratory alteration ( elevate liver enzymes twice ashigh upper normal limit ; 2 . Diabetic patient , fast glucose value superior 110mg/dl ; 3 . Significant lipid profile alteration ( triglyceride &gt; 300 mg/dl ; total cholesterol &gt; 250 mg/dl ) ; 4 . Low count white blood cell ( leukocytes &lt; 3000/mm3 ) ; 5 . History hypersensitivity isotretinoin parabens ; 6 . Alcohol intake ; 7 . Previous actual history rheumatologic diseases ; 8 . Anticancer chemotherapy last 3 month ; 9 . Previous history hypervitaminosis A ; 10 . Previous history bone muscular disease ; 11 . Patients use may use follow drug ( risk drug interaction ) : tetracycline derivative last 7 day ; vitamin A last 30 day ; carbamazepine last 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>actinic keratosis</keyword>
	<keyword>tretinoin</keyword>
	<keyword>isotretinoin</keyword>
	<keyword>cryotherapy</keyword>
	<keyword>sun protection factor</keyword>
	<keyword>clinical clearance</keyword>
</DOC>